Simulations Plus, Inc. logo SLP - Simulations Plus, Inc.

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY 0
BUY 4
HOLD 4
SELL 0
STRONG
SELL 0
| PRICE TARGET: $56.00 DETAILS
HIGH: $65.00
LOW: $47.00
MEDIAN: $56.00
CONSENSUS: $56.00
UPSIDE: 264.35%

Stock News

Simulations Plus to Participate in the 23rd Annual Craig-Hallum Institutional Investor Conference

Simulations Plus to Participate in the 23rd Annual Craig-Hallum Institutional Investor Conference

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced that Shawn O'Connor, Chief Executive Officer, will be participating in the 23rd Annual Craig-Hallum Institutional Investor Conference taking place in Minneapolis, Minnesota. Mr. O'Connor will host one-on-one meetings with institutional investors on Thurs.

May 21, 2026 12:05 PM • businesswire.com
Simulations Plus and NVIDIA Collaborate to Scale GPU-Accelerated, AI-Assisted Modeling Workflows

Simulations Plus and NVIDIA Collaborate to Scale GPU-Accelerated, AI-Assisted Modeling Workflows

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced the launch of a technical collaboration with NVIDIA focused on enabling GPU-accelerated simulation and AI-assisted workflows for computationally intensive modeling applications within the drug development lifecycle. The collaboration brings together Simu.

May 06, 2026 03:55 AM • businesswire.com
Simulations Plus Announces Collaboration with Lonza and U.S. FDA to Advance Predictive Frameworks for Complex Oral Drug Products

Simulations Plus Announces Collaboration with Lonza and U.S. FDA to Advance Predictive Frameworks for Complex Oral Drug Products

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced a funded research collaboration with Lonza Group AG (“Lonza”), a leading contract development and manufacturing organization (CDMO) dedicated to serving the healthcare industry, and the U.S. Food and Drug Administration (FDA) to develop and validate a me.

Apr 21, 2026 03:55 AM • businesswire.com
Simulations Plus Expands Global Access to Model-Informed Drug Development Training Through Its 2026 Spring School

Simulations Plus Expands Global Access to Model-Informed Drug Development Training Through Its 2026 Spring School

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced the successful completion of its 2026 Spring School, a global training initiative designed to expand access to model-informed drug development (MIDD) and strengthen the scientific foundation of the industry's future workforce. More than 1,400 scientists.

Apr 20, 2026 03:55 AM • businesswire.com
Reviewing Smith Micro Software (NASDAQ:SMSI) & Simulations Plus (NASDAQ:SLP)

Reviewing Smith Micro Software (NASDAQ:SMSI) & Simulations Plus (NASDAQ:SLP)

Smith Micro Software (NASDAQ: SMSI - Get Free Report) and Simulations Plus (NASDAQ: SLP - Get Free Report) are both small-cap computer and technology companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, profitability, risk, dividends, earnings and institutional ownership. Volatility and Risk Smith

Apr 14, 2026 10:17 PM • defenseworld.net
Simulations Plus Reports Second Quarter Fiscal 2026 Financial Results

Simulations Plus Reports Second Quarter Fiscal 2026 Financial Results

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today reported financial results for its second quarter fiscal 2026, ended February 28, 2026. Second Quarter 2026 Financial Highlights (as compared to second quarter 2025) Total revenue increased 8% to $24.3 million Software revenue increased 9% to $14.6 million, repres.

Apr 09, 2026 12:05 PM • businesswire.com
Simulations Plus Announces Second Quarter Fiscal Year 2026 Earnings and Conference Call Date

Simulations Plus Announces Second Quarter Fiscal Year 2026 Earnings and Conference Call Date

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”, “SLP”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced that it will report second quarter fiscal 2026 financial results after the market close on Thursday, April 9, 2026. Management will host a conference call that same day at 5:00 p.m. Eastern Time to discuss the results. Investment professionals and all current and.

Mar 26, 2026 12:05 PM • businesswire.com
Simulations Plus Announces Strategic Collaboration Programs for AI-Enabled Modeling

Simulations Plus Announces Strategic Collaboration Programs for AI-Enabled Modeling

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced strategic collaboration programs with three large pharmaceutical companies to advance artificial intelligence (AI) workflows across the drug development lifecycle. These programs apply AI within scientifically grounded modeling workflows and define how n.

Mar 26, 2026 03:55 AM • businesswire.com
Simulations Plus Convenes Industry and Regulatory Leaders to Define Responsible AI in MIDD

Simulations Plus Convenes Industry and Regulatory Leaders to Define Responsible AI in MIDD

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced a high-impact panel discussion, “From Debate to Deployment: Responsible, Practical AI in MIDD,” to be held during the upcoming American Society for Clinical Pharmacology & Therapeutics (ASCPT) Annual Meeting on March 5, 2026 at 12:00 PM MST in Denver.

Mar 03, 2026 02:55 AM • businesswire.com
ROSEN, A LONGSTANDING FIRM, Encourages Simulations Plus, Inc. Investors to Inquire About Securities Class Action Investigation - SLP

ROSEN, A LONGSTANDING FIRM, Encourages Simulations Plus, Inc. Investors to Inquire About Securities Class Action Investigation - SLP

New York, New York--(Newsfile Corp. - February 11, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Simulations Plus, Inc. (NASDAQ: SLP) resulting from allegations that Simulations Plus may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Simulations Plus securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

Feb 11, 2026 11:22 AM • newsfilecorp.com (Hide legal announcements)

Price Targets